788 related articles for article (PubMed ID: 8874972)
1. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
Qadri SM; Ueno Y; Cunha BA
Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of BRL 42715, a beta-lactamase-inhibiting penem.
Qadri SM; Ueno Y; Burdette M; Kroschinsky R; Almodovar E
Chemotherapy; 1991; 37(6):398-404. PubMed ID: 1760938
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
Anuradha K; Sailaja VV; Umabala P; Satheesh T; Lakshmi V
Indian J Med Microbiol; 2007 Jul; 25(3):203-8. PubMed ID: 17901635
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
Fass RJ; Prior RB
Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
[TBL] [Abstract][Full Text] [Related]
6. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
Piddock LJ; Jin YF; Turner HL
J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of gram-negative bacteria and Staphylococcus aureus to combinations of ticarcillin and clavulanic acid.
Casey P; Glauser M
Eur J Clin Microbiol; 1983 Dec; 2(6):541-7. PubMed ID: 6607834
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
9. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Livermore DM; Seetulsingh P
J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
[TBL] [Abstract][Full Text] [Related]
11. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
Leclercq R; Duval J
Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
[TBL] [Abstract][Full Text] [Related]
12. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the in vitro activity of piperacillin/tazobactam.
Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Pagani L; Migliavacca R; Luzzaro F; Giacobone E; Perilli M; Micheletti P; Amicosante G
Chemotherapy; 1998; 44(6):377-84. PubMed ID: 9755296
[TBL] [Abstract][Full Text] [Related]
15. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
Knapp CC; Sierra-Madero J; Washington JA
Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
[TBL] [Abstract][Full Text] [Related]
16. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
19. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
Lister PD
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
[TBL] [Abstract][Full Text] [Related]
20. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
Thomson KS; Weber DA; Sanders CC; Sanders WE
Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
